With its new Special Protocol Assessment with the U.S. Food and Drug Administration, CorMedix will be conducting Phase III research for Deferiprone as an indication for Contrast-Induced Acute Kidney Injury. Often times, the importance or value of an SPA is overlooked, but it the case of CorMedix, it certainly warrants a closer look.

A portion of the article:

CorMedix (AMEX: CRMD) announced that it received a Special Protocol Assessment approval letter from the FDA on the design of a pivotal Phase 3 trial for Deferiprone. Deferiprone is indicated for Contrast-Induced Acute Kidney Injury. The “SPA” takes into consideration a modification to the dosing regimen contained in the previously submitted protocol.

National Health Partners, Inc. (NHPR)

National Health Partners, Inc primary target customer group is the 47 million Americans who have no health insurance of any kind. The company's secondary target customer group includes the millions of Americans who lack complete health insurance coverage.

American Video Teleconferencing Corp. (AVOT)